Arcturus, Ultragenyx ally in rare disease pact worth up to $1.6bn; deal expanded
RNA-focused start-up Arcturus Therapeutics Inc. (ATI) and fellow rare disease therapeutics developer Ultragenyx Pharmaceutical Inc. will collaborate on the discovery and development of messenger RNA (mRNA) therapeutics for up to ten select undisclosed rare disease targets, using Arcturus' UNA (Unlocked Nucleomonomer Agent) and LUNAR enabling technologies.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com